For the year to December 31, 2007 SG&A included a charge of $52.7 million for share based compensation (2006: $34.4 million), which included a $22.5 million cumulative catch up charge in respect of 2005 awards, see page 18.
Depreciation and amortization
The depreciation charge for the year to December 31, 2007 was $59.3 million (2006: $43.3 million), inclusive of impairment charges of $1.8 million (2006: $0.5 million). The increase in depreciation follows investment in Shire's infrastructure to support the continuing growth of the Company.
The amortization charge for the year to December 31, 2007 was $95.0 million (2006: $57.4 million), inclusive of impairment charges of $0.4 million (2006: $1.1 million). The increased charge is primarily due to the amortization of DAYTRANA, DYNEPO and VYVANSE intangible assets following the product launches in June 2006, March 2007 and July 2007 respectively.
For the year to December 31, 2007 Shire incurred $1.3 million of costs associated with the integration of the New River business (2006: $5.6 million relating to the TKT acquisition). New River is now fully integrated and no further integration costs are anticipated.
Gain on sale of product rights
For the year to December 31, 2007 Shire recognized gains of $127.8 million on the sale of non-core products.
Shire received $209.6 million (net of costs of $2.2 million) from
Almirall for a portfolio of non core products comprising the dermatology
products SOLARAZE and VANIQA and six non-promoted products across a range
of indications, which were sold by Shire primarily in the UK, France,
Germany, Italy, Spain and Ireland. This sal
|SOURCE Shire plc|
Copyright©2008 PR Newswire.
All rights reserved